Skip to main content
Venus Remedies Ltd. logo

Venus Remedies Ltd. — Investor Relations & Filings

Ticker · VENUSREM ISIN · INE411B01019 LEI · 335800PBHMB6GQMFN127 BSE.NS Manufacturing
Open in API
Filings indexed 622 across all filing types
Latest filing 2025-08-01 Interim / Quarterly Rep…
Country IN India
Listing BSE.NS VENUSREM

About Venus Remedies Ltd.

https://venusremedies.com/

Venus Remedies Ltd. is a research-driven organization specializing in the development and manufacturing of innovative pharmaceutical formulations. The company focuses on critical therapeutic segments, including antimicrobial resistance, oncology, neurology, orthopedics, and pain management. It operates advanced manufacturing facilities and maintains a dedicated research and development wing, the Venus Medicine Research Centre, which prioritizes the creation of novel drug delivery systems and solutions for multi-drug resistant infections. Its product portfolio features a diverse range of injectables and specialized treatments, such as Elores, aimed at addressing complex clinical needs. The company serves a global market, providing healthcare solutions through a commitment to scientific excellence and international regulatory standards.

Recent filings

Filing Released Lang Actions
Outcome of Board Meeting
Interim / Quarterly Report Classification · 93% confidence The document is a board meeting outcome announcing the unaudited quarterly consolidated and standalone financial results for the period ended 30 June 2025, including the detailed financial tables and an auditor’s limited review report. It contains full interim financial statements, meeting minutes timing, and SEBI Regulation 33 reference, which is characteristic of an Interim/Quarterly Report rather than just a headline earnings release or a report publication notice. Q1 2026
2025-08-01 English
Updates
Regulatory Filings Classification · 100% confidence The document text is extremely short (66 characters) and contains only a digital signature with no substantive content or financial data. There is no indication of any report, announcement, or detailed information. Given the lack of content, this is likely a regulatory filing or a minimal attestation document. According to the rules, such minimal content defaults to Regulatory Filings (RNS).
2025-07-29 English
Copy of Newspaper Publication
Interim / Quarterly Report Classification · 95% confidence The document is a lengthy text (15,000 characters) primarily in Hindi, containing detailed company news, financial figures, and business updates. It includes references to financial performance metrics such as profits, revenues, and operational details for various companies, including Bajaj, Petronet, and others. The text discusses quarterly or half-yearly financial results, mentioning specific periods like April-June and fiscal years 2024-25 and 2025-26. There is no indication that this is a short announcement or a certification letter; rather, it contains substantive financial data and analysis for a period shorter than a full fiscal year. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q1 2026
2025-07-26 English
Shareholders meeting
Annual Report Classification · 100% confidence The document is titled 'Venus Remedies Limited Annual Report 2024-25' and contains extensive content typical of an annual report, including sections such as Management Discussion & Analysis, Directors' Report, Corporate Governance Report, Standalone and Consolidated Financial Statements, Key Performance Indicators, and Corporate Overview. The length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement. The presence of detailed financial data, strategic narratives, and comprehensive corporate information confirms this is the official yearly report covering company activity and full financial performance. Therefore, the document fits the definition of an Annual Report (10-K). FY 2025
2025-07-24 English
Board Meeting — Board Meeting Intimation
Regulatory Filings
2025-07-22 English
Board Meeting — Financial Results
Regulatory Filings Classification · 100% confidence The document text is extremely short (only 68 characters) and contains only a digital signature with a date. There is no substantive content, financial data, or report information. It does not contain any report, announcement, or detailed information. Given the lack of content, this is best classified as a Regulatory Filing (RNS) as a fallback category for miscellaneous filings that do not fit other categories.
2025-07-22 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.